Abstract
Mesalazine is widely used in the treatment of inflammatory bowel disease. Little is known about the dose-response relationship and about possible dose related side effects. In ulcerative colitis higher dosages of mesalazine (3 g) are more effective in maintaining a remission than lower dosages (1.5 g). In mild to moderately active ulcerative colitis, studies also indicate that higher dosages might be more effective in inducing remission. Dose-comparing studies in Crohn's disease are even more sparse, but the available results indicate higher efficacy at higher dose levels. None of the known side effects of mesalazine are clearly dose-related. A pH-dependent release system, however, can cause a sudden release of high doses of mesalazine. Consequent peak levels in serum have been implicated in mesalazine induced nephrotoxicity. In conclusion, despite the current practice of using increasing dosages of mesalazine in inflammatory bowel disease, both efficacy and safety have been established tentatively.
Full Text
The Full Text of this article is available as a PDF (91.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Azad Khan A. K., Howes D. T., Piris J., Truelove S. C. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut. 1980 Mar;21(3):232–240. doi: 10.1136/gut.21.3.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
- Fockens P., Mulder C. J., Tytgat G. N., Blok P., Ferwerda J., Meuwissen S. G., Tuynman H. A., Dekker W., Gasthuis K., van Hees P. A. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur J Gastroenterol Hepatol. 1995 Nov;7(11):1025–1030. doi: 10.1097/00042737-199511000-00003. [DOI] [PubMed] [Google Scholar]
- Hanauer S. B. Inflammatory bowel disease. N Engl J Med. 1996 Mar 28;334(13):841–848. doi: 10.1056/NEJM199603283341307. [DOI] [PubMed] [Google Scholar]
- Hanauer S., Schwartz J., Robinson M., Roufail W., Arora S., Cello J., Safdi M. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol. 1993 Aug;88(8):1188–1197. [PubMed] [Google Scholar]
- Järnerot G. New salicylates as maintenance treatment in ulcerative colitis. Gut. 1994 Sep;35(9):1155–1158. doi: 10.1136/gut.35.9.1155. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pent M. T., Ganapathy S., Holdsworth C. D., Channer K. C. Mesalazine induced lupus-like syndrome. BMJ. 1992 Jul 18;305(6846):159–159. doi: 10.1136/bmj.305.6846.159-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rünzi M., Layer P. Drug-associated pancreatitis: facts and fiction. Pancreas. 1996 Jul;13(1):100–109. doi: 10.1097/00006676-199607000-00014. [DOI] [PubMed] [Google Scholar]
- Schroeder K. W., Tremaine W. J., Ilstrup D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987 Dec 24;317(26):1625–1629. doi: 10.1056/NEJM198712243172603. [DOI] [PubMed] [Google Scholar]
- Singleton J. W., Hanauer S. B., Gitnick G. L., Peppercorn M. A., Robinson M. G., Wruble L. D., Krawitt E. L. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 1993 May;104(5):1293–1301. doi: 10.1016/0016-5085(93)90337-c. [DOI] [PubMed] [Google Scholar]
- Sutherland L. R., May G. R., Shaffer E. A. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med. 1993 Apr 1;118(7):540–549. doi: 10.7326/0003-4819-118-7-199304010-00009. [DOI] [PubMed] [Google Scholar]